Myocardial Infarction Global Clinical Trials Review, H1, 2018
Myocardial Infarction Global Clinical Trials Review, H1, 2018
Summary
GlobalData's clinical trial report, “Myocardial Infarction Global Clinical Trials Review, H1, 2018" provides an overview of Myocardial Infarction clinical trials scenario. This report provides top line data relating to the clinical trials on Myocardial Infarction. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned in the Report
AstraZeneca Plc
Sanofi
C. H. Boehringer Sohn AG & Co KG
Merck & Co Inc
Pfizer Inc
Eli Lilly and Co
GlaxoSmithKline Plc
Daiichi Sankyo Co Ltd
Medtronic Plc
Bristol-Myers Squibb Co
2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Myocardial Infarction to Cardiovascular Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Myocardial Infarction to Cardiovascular Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Myocardial Infarction Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Myocardial Infarction 31
Feb 07, 2018: Brilinta significantly reduces CV events and coronary death beyond one year in heart attack survivors with multi-vessel disease 31
Clinical Trial Profile Snapshots 32
Appendix 835
Abbreviations 835
Definitions 835
Research Methodology 836
Secondary Research 836
About GlobalData 837
Contact Us 837
Source 837List of Tables
Myocardial Infarction Therapeutics, Global, Clinical Trials by Region, 2018* 7
Myocardial Infarction Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Myocardial Infarction Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Myocardial Infarction Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Myocardial Infarction Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Myocardial Infarction Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Myocardial Infarction Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
Myocardial Infarction Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
Proportion of Myocardial Infarction to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 16
Myocardial Infarction Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Myocardial Infarction Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Myocardial Infarction to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 19
Myocardial Infarction Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Myocardial Infarction Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Myocardial Infarction Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Myocardial Infarction Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Myocardial Infarction Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Myocardial Infarction Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Myocardial Infarction Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Myocardial Infarction Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Myocardial Infarction Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Myocardial Infarction Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Myocardial Infarction Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30List of Figures
Myocardial Infarction Therapeutics, Global, Clinical Trials by Region (%), 2018* 7
Myocardial Infarction Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 8
Myocardial Infarction Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Myocardial Infarction Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Myocardial Infarction Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Myocardial Infarction Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Myocardial Infarction Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
Myocardial Infarction Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
Proportion of Myocardial Infarction to Cardiovascular Clinical Trials, G7 Countries (%), 2018* 16
Myocardial Infarction Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Myocardial Infarction Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Myocardial Infarction to Cardiovascular Clinical Trials, E7 Countries (%), 2018* 19
Myocardial Infarction Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Myocardial Infarction Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Myocardial Infarction Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Myocardial Infarction Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Myocardial Infarction Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Myocardial Infarction Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Myocardial Infarction Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Myocardial Infarction Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Myocardial Infarction Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Myocardial Infarction Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Myocardial Infarction Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 836
Research Methodology
The research study released with title "Myocardial Infarction Global Clinical Trials Review, H1, 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Myocardial Infarction Global Clinical Trials Review. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Myocardial Infarction Global Clinical Trials Review who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Myocardial Infarction Global Clinical Trials Review as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Myocardial Infarction Global Clinical Trials Review study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Myocardial Infarction Global Clinical Trials Review, H1, 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
